InspireMD Q2 2024 Earnings Report $2.94 +0.22 (+8.09%) As of 03:57 PM Eastern Earnings HistoryForecast InspireMD EPS ResultsActual EPS-$0.22Consensus EPS -$0.19Beat/MissMissed by -$0.03One Year Ago EPS-$0.24InspireMD Revenue ResultsActual Revenue$1.74 millionExpected Revenue$1.74 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AInspireMD Announcement DetailsQuarterQ2 2024Date8/6/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseNSPR Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by InspireMD Earnings HeadlinesHere's Why We're Watching InspireMD's (NASDAQ:NSPR) Cash Burn SituationJanuary 14, 2025 | finance.yahoo.comInspireMD, Inc.: InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025December 12, 2024 | finanznachrichten.deDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. January 21, 2025 | Crypto 101 Media (Ad)InspireMD Finance Chief Craig Shore To RetireDecember 12, 2024 | markets.businessinsider.comInspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025December 12, 2024 | finance.yahoo.comLake Street Initiates Coverage of InspireMD (NSPR) with Buy RecommendationDecember 12, 2024 | msn.comSee More InspireMD Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like InspireMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InspireMD and other key companies, straight to your email. Email Address About InspireMDInspireMD (NYSE:NSPR), a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.View InspireMD ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025)ICICI Bank (1/22/2025)Johnson & Johnson (1/22/2025)Kinder Morgan (1/22/2025)Procter & Gamble (1/22/2025)Progressive (1/22/2025)Travelers Companies (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
